Clinical Trials Directory

Trials / Completed

CompletedNCT04744818

Effects of Iron Supplementation on Pediatric Vaccine Response

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
288 (actual)
Sponsor
Jessica Rigutto · Academic / Other
Sex
All
Age
39 Days – 45 Days
Healthy volunteers
Accepted

Summary

ID/IDA affects many young children in Africa. Vaccines provide tremendous benefits in LMIC; however, they currently fail to reach their full potential. We need to better understand the causes of vaccine failure, in order to develop new strategies to improve vaccine immunogenicity. This study will contribute to children's health by: (1) providing updated guidelines to better define the prevalence of ID/IDA in early infancy, and its safe and effective control using iron; and (2) providing a new approach to improve response to pediatric vaccines in LMIC, by ensuring adequate iron status at time of vaccination.

Detailed description

Two major pediatric public health goals in LMIC are increasing immunization effectiveness and reducing ID/IDA in children. ID/IDA affects many young children in Africa. Current guidelines do not recommend routine testing of hemoglobin in early infancy, as it is generally believed that most infants are born with adequate iron stores to last 6 months. However, many African infants are born with low iron stores and ID/IDA may develop earlier than generally appreciated, within 2-3 months after birth. Vaccines provide tremendous benefits in LMIC; however, they currently fail to reach their full potential. We need to better understand the causes of vaccine failure, in order to develop new strategies to improve vaccine immunogenicity. Despite lower efficacy in LMIC, these vaccines provide a major benefit because the disease burden is so high; however, if approaches can be found to improve immunogenicity, these vaccines would be even more powerful. For this study, 6 weeks old infants will be randomly assigned to two study groups. Group 1 will receive iron at time of pediatric vaccinations from age 6-24 weeks. Group 2 will receive no iron at time of pediatric vaccinations. All infants will receive a multivitamin syrup from age 6-24 weeks. All infants remaining ID/IDA at age 24 weeks will receive iron. Infants will be followed-up until age 52 weeks.

Conditions

Interventions

TypeNameDescription
DIETARY_SUPPLEMENTIron syrupDaily supplementation with iron
DIETARY_SUPPLEMENTMultivitamin syrupDaily supplementation with multivitamins

Timeline

Start date
2021-02-07
Primary completion
2023-04-03
Completion
2023-10-16
First posted
2021-02-09
Last updated
2024-01-24

Locations

2 sites across 2 countries: Kenya, Switzerland

Source: ClinicalTrials.gov record NCT04744818. Inclusion in this directory is not an endorsement.